A Phase 1 interventional study of Mirikizumab Prefilled Syringe and Mirikizumab Autoinjector in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.
Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 milliliter (mL) mirikizumab as 2 subcutaneous (SC) injections of 1 mL and 2 mL delivered via a prefilled syringe (PFS) to abdomen or arms or thighs.
Drug: Mirikizumab Prefilled Syringe
Participants received 3 mL mirikizumab as 2 SC injections of 1 mL and 2 mL delivered an autoinjector (AI) to abdomen or arms or thighs.
Drug: Mirikizumab Autoinjector
Administered SC by prefilled syringe
Also known as: LY3074828
Administered SC by autoinjector
Also known as: LY3074828
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI
PK: Cmax of Mirikizumab administered by PFS and AI.
Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab Administered by PFS and AI
PK: AUC\[0-∞\] of Mirikizumab administered by PFS and AI.
Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab Administered by PFS and AI
PK: AUC\[0-tlast\] of Mirikizumab administered by PFS and AI.
Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose
| Milestone | Mirikizumab Pre-filled Syringe (PFS) - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab Autoinjector (AI) - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh |
|---|---|---|---|---|---|---|
| Started | 39 | 39 | 39 | 40 | 40 | 40 |
| Received at least one dose of study drug | 39 | 39 | 39 | 40 | 40 | 40 |
| Completed | 39 | 38 | 37 | 40 | 39 | 38 |
| Not completed | 0 | 1 | 2 | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 | 2 |
PK: Cmax of Mirikizumab administered by PFS and AI.
| micrograms per milliliter (μg/mL) | Mirikizumab PFS | Mirikizumab AI |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI | 20.0 ± 44 | 23.5 ± 40 |
PK: AUC\[0-∞\] of Mirikizumab administered by PFS and AI.
| microgram*day per milliliter (μg*day/mL) | Mirikizumab PFS | Mirikizumab AI |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab Administered by PFS and AI | 359 ± 44 | 412 ± 39 |
PK: AUC\[0-tlast\] of Mirikizumab administered by PFS and AI.
| microgram*day per milliliter (μg*day/mL) | Mirikizumab PFS | Mirikizumab AI |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab Administered by PFS and AI | 355 ± 44 | 411 ± 38 |
Collected over Baseline up to 88 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mirikizumab PFS - Abdomen | 0/39 (0%) | 0/39 (0%) | 8/39 (20.5%) |
| Mirikizumab PFS - Arm | 0/39 (0%) | 0/39 (0%) | 13/39 (33.3%) |
| Mirikizumab PFS - Thigh | 0/39 (0%) | 0/39 (0%) | 8/39 (20.5%) |
| Mirikizumab AI - Abdomen | 0/40 (0%) | 1/40 (2.5%) | 13/40 (32.5%) |
| Mirikizumab AI - Arm | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| Mirikizumab AI - Thigh | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| Event | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh |
|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/19 | 0/25 | 0/22 | 1/21 | 0/29 | 0/22 |
| Event | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/39 | 6/39 | 2/39 | 1/40 | 3/40 | 4/40 |
| Injection site reactionGeneral disorders | 0/39 | 1/39 | 1/39 | 6/40 | 5/40 | 1/40 |
| COVID-19Infections and infestations | 1/39 | 3/39 | 3/39 | 4/40 | 4/40 | 2/40 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/39 | 3/39 | 0/39 | 1/40 | 1/40 | 2/40 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/39 | 3/39 | 0/39 | 1/40 | 0/40 | 0/40 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/39 | 2/39 | 0/39 | 0/40 | 1/40 | 3/40 |
| DiarrhoeaGastrointestinal disorders | 1/39 | 2/39 | 0/39 | 2/40 | 1/40 | 0/40 |
| NauseaGastrointestinal disorders | 0/39 | 2/39 | 2/39 | 1/40 | 1/40 | 0/40 |
| VomitingGastrointestinal disorders | 2/39 | 1/39 | 0/39 | 0/40 | 1/40 | 1/40 |
| FatigueGeneral disorders | 0/39 | 0/39 | 2/39 | 0/40 | 1/40 | 1/40 |
All participants who received at least one dose of mirikizumab.
| Age, Continuous(years) | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.7 ± 12.7 | 39.2 ± 11.6 | 42.5 ± 13.2 | 42.1 ± 14.4 | 42.6 ± 13.0 | 39.1 ± 12.8 | 41.3 ± 12.9 |
| Sex: Female, Male(Participants) | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh | Total |
|---|---|---|---|---|---|---|---|
| Female | 19 | 25 | 22 | 21 | 29 | 22 | 138 |
| Male | 20 | 14 | 17 | 19 | 11 | 18 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 13 | 8 | 9 | 8 | 48 |
| Not Hispanic or Latino | 33 | 35 | 26 | 32 | 31 | 32 | 189 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 0 | 0 | 3 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 5 | 4 | 8 | 3 | 29 |
| White | 32 | 33 | 33 | 35 | 29 | 36 | 198 |
| More than one race | 1 | 0 | 1 | 1 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Mirikizumab PFS - Abdomen | Mirikizumab PFS - Arm | Mirikizumab PFS - Thigh | Mirikizumab AI - Abdomen | Mirikizumab AI - Arm | Mirikizumab AI - Thigh | Total |
|---|---|---|---|---|---|---|---|
| United States | 39 | 39 | 39 | 40 | 40 | 40 | 237 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Jun 2022, 8 months.
Results were first posted in Mar 2025, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab